Wearable Patch Enables Continuous Troponin Monitoring for Postoperative Cardiac Injury

By HospiMedica International staff writers
Posted on 20 Nov 2026

Myocardial injury after noncardiac surgery (MINS) is heart muscle damage that occurs following procedures not involving the heart. Detecting MINS is challenging because most cases are asymptomatic and may occur after patients leave the hospital. With approximately 300 million people undergoing noncardiac surgery worldwide each year, identifying postoperative heart injury is particularly important for high-risk patients.

Researchers at McMaster University have developed a wearable patch designed to continuously monitor cardiac troponin, a protein released when the heart is injured. The patch uses microscopic polymer microneedles that penetrate just beneath the skin without reaching nerves or blood vessels. These microneedles collect interstitial fluid and deliver it to a biosensor, enabling cardiac troponin levels to be tracked over several days.


Image: The wearable device uses microscopic polymer needles that penetrate just beneath the skin, without reaching nerves or blood vessels. (Photo courtesy of Angelica Marie Sanchez/University of Waterloo)

The technology addresses a difficult sensing problem because cardiac troponin is present at very low concentrations in blood and is further diluted in interstitial fluid. To detect proteins, the research team combined antibodies that recognize proteins with aptamers that generate a measurable signal. Aptamers are short strands of DNA or RNA engineered to identify specific biological targets.

The project involved multiple institutions and disciplines. Researchers at the University of Waterloo developed the microneedle technology needed for continuous sampling. At McMaster, the technology was tested in living systems, including mouse models of heart disease, as a step toward understanding its potential future clinical use.

The findings were published in Science Advances on November 18, 2026. The work builds on earlier biosensing and aptamer engineering that had been used to monitor smaller molecules such as lactate. The research team plans additional testing and is pursuing commercialization through Aptec Health, with postsurgical monitoring as the immediate focus.

“About 90% of these cases are silent. The only way to diagnose many of them is through a blood test, which is difficult when patients are already home. We wanted to develop a way to continuously monitor for heart injuries without requiring repeated blood draws,” said Leyla Soleymani, professor of engineering physics and lead of engineering innovation at NexusHealth.

“Creating microneedles that can sample interstitial fluid comfortably and painlessly over extended periods and integrating them with sensing electrodes were key steps toward continuous wearable sensing,” said Mahla Poudineh, now an associate professor at the NYU Tandon School of Engineering.

Related Links
McMaster University
University of Waterloo


Latest Critical Care News